Camargo

APRIL 20, 2021

Oncology therapies typically have a comparatively shorter lab-to-clinic turnaround time than therapeutics targeting other diseases. Biotech companies developing oncology assets thus tend to reach the clinical-stage value inflection point faster than sponsors of other therapies do. A strong IP position.

Development 137

Development Genotoxicity Production Drugs 137

The Pharma Data

FEBRUARY 8, 2021

Across clinical trials (PALOMA-1, PALOMA-2, PALOMA-3), 1.0% IBRANCE may impair fertility in males and has the potential to cause genotoxicity. DISCLOSURE NOTICE : The information contained in this release is as of February 5, 2021. of IBRANCE-treated patients had ILD/pneumonitis of any grade, 0.1%

HR 52

HR Clinical Trials Clinical Trials Containment 52

The Pharma Data

APRIL 14, 2021

Accelerated Approval Granted for Locally Advanced or Metastatic Urothelial Cancer Following a Platinum-Containing Chemotherapy and a PD-1/PD-L1 Inhibitor –. – New Indication Marks Second FDA Approval for Trodelvy in 2021 –. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. FOSTER CITY, Calif.–(BUSINESS

Genotype 52

Genotype Containment FDA Approval Genotoxicity 52

The Pharma Data

MAY 13, 2021

Fructose Containing Sugars at Normal Levels of Consumption Do Not Effect Adversely Components of the Metabolic Syndrome and Risk Factors for Cardiovascular Disease. Exposure to sorbitol during lactation causes metabolic alterations and genotoxic effects in rat offspring. Arq Gastroenterol. 2014 AprJun;51(2):118-22. PMID: 25003263.

Insulin 52

Insulin Production Hormones Medicine 52